Skip to main content
BMC Geriatrics logoLink to BMC Geriatrics
. 2025 Jul 5;25:501. doi: 10.1186/s12877-025-06167-2

Sarcopenia as a predictor of mortality in centenarians: insights from a prospective cohort study

Yun Tang 1,#, Hongyan Lin 1,#, Meijuan Chen 1, Yuanyuan Zhong 1, Xiaochu Wu 2, Li Wang 1,✉
PMCID: PMC12229006  PMID: 40618016

Abstract

Background & aims

Centenarians represent a unique population where predictors of mortality are understudied.Studies have shown that sarcopenia is associated with adverse health outcomes and premature death in elderly patients. The aim of our study was to explore the association between sarcopenia and centenarian mortality.

Methods

Our study is a prospective cohort study. Muscle mass was measured using bioelectrical impedance analysis (BIA), and the relative skeletal muscle index (RSMI) was adjusted for height to reduce individual differences. Sarcopenia is defined according to the Asian Sarcopenia Working Group’s (AWGS)2019 updated diagnostic criteria for sarcopenia, it introduces the concept of “possible sarcopenia”, defined as the presence of only low muscular strength or low physical performance, specifically for primary health care or community health promotion to enable earlier lifestyle interventions. The survival time of centenarians with and without sarcopenia was compared using the Kaplan-Meier method, and the hazard ratio (HR) and 95% confidence interval (95% CI) for mortality were determined using the Cox proportional hazards regression model.

Results

A total of 98 centenarians were included in this study, with an average age of (102.2 ± 1.8) years. The prevalence of sarcopenia was 20.4%. The Cox proportional hazards model analysis showed that after adjusting for confounding factors, the risk of death was increased by 3.64 times in the sarcopenia group (HR = 4.64, 95% CI: 2.48–8.66).

Conclusion

Sarcopenia can serves as a significant predictor of long-term mortality in centenarians and functions as an important independent predictor.

Trial registration

The trial was registered at the Chinese Clinical Trial Center on 17-01-2019. Trial registration numbers 2018 − 463; ChiCTR1900020754.

Keywords: Centenarian, Sarcopenia, Long-term death, Predictor, Risk factors, Healthy aging

Background

According to WHO data, the global population is aging rapidly. It is projected that the number of people over 60 will increase from 1 billion to 1.4 billion between 2020 and 2030 [1]. The number of centenarians (people over 100) has also risen significantly, with nearly half a million in 2015. By 2100, it is estimated that there will be over 25 million centenarians, more than fifty times the number in 2015 [2].

Sarcopenia is a clinical condition that has received more attention in recent years. Its characteristic is a muscle mass reduction that is age-related, accompanied by low muscle strength or impaired physical function [3–5]. It was first described by Rosenberg [6]. It is one of the main health problems of the elderly and increases the risk of disability, falls and fall-related injuries, hospitalization time, and mortality [7, 8]. Cheung and colleagues reported that the appendicular lean mass (ALM) alone and ALM adjusted for body mass index could predict mortality in the National Health and Nutrition Examination Survey 1999–2004 [9]. Mesut Gumuşsoy et al. reported that elderly hospitalized patients with sarcopenia had a close relationship with the all-cause mortality rate during hospitalization [10]. Young Eun Kwon et al. confirmed that sarcopenia can be an effective predictor of all-cause mortality in elderly patients [11].

Previous studies have prospectively evaluated the risk factors for death in centenarians. Factors such as disability, limited mobility, cognitive impairment, and declining physical functioning, as well as body mass index (BMI), serum albumin, visual or hearing impairment, dementia, and alcohol consumption, are positively correlated with mortality [12–15]. A 2019 paper utilized anthropometric equations to evaluate muscle mass in individuals aged 90 and centenarians, investigating the correlation between muscle mass deficiency and all-cause mortality in the elderly population. The study revealed that low muscle mass serves as a significant predictor of long-term mortality in women aged 90 and centenarians. However, the low muscle mass in this study was calculated based on the equation derived from Chinese people aged 18 to 69, and there might be certain biases in the study [16]. Above all, none of these designs are specifically designed for centenarians, and, there have been no reported studies on the impact of sarcopenia, an age-related disease associated with aging, on the mortality of centenarians. Centenarians are often considered a special “escaper” group that may have elasticity to common diseases due to their physiological and pathological characteristics. Then, it is still unclear whether it has a special resistance to sarcopenia, whether sarcopenia can be used as a sign of old age, frailty and disability, and whether it increases the risk of death for centenarians.

Therefore, this study aims to measure the muscle mass, muscle strength and physical activity ability of centenarians by using bioelectrical impedance analysis (BIA), screen the incidence of sarcopenia in centenarians, and for the first time propose that sarcopenia can serves as a predictive indicator of the risk of death in centenarians.

Methods

Experiment flow chart

graphic file with name 12877_2025_6167_Figa_HTML.jpg

The study population

This is a prospective cohort study conducted in the Leshan area of Sichuan Province in 2019 to investigate the relationship between sarcopenia, environment, gut microbiota, nutritional status, education level, cognitive function, cardiovascular chronic diseases and longevity. We collected blood and stool specimens and related data from all centenarians registered by the local government in 2019. Inclusion criteria: age ≥ 100 years old; Long-term resident in the study area; Voluntarily sign informed consent. Exclusion criteria: No permanent place to live or refuse to provide contact information; End-stage malignant tumor (expected survival < 3 months, clinical diagnosis required); Severe physical dysfunction Or near death(Barthel index < 20, complete dependence on others for care). A total of 108 subjects were screened, and 3 died during the preparation period, while 7 refused to participate in the study. No data were excluded, and ultimately, 98 subjects (25 males and 73 females) were included in our study.

Ethical considerations

The data collection was approved by the Ethics Committee of Leshan People’s Hospital (Le shi Hospital Committee [2019] No.15). All participants (or their legal representatives) signed a written informed consent form. This study strictly adhered to the ethical standards stipulated in the 1995 Helsinki Declaration (revised in Edinburgh in 2000), encompassing the principles of autonomy, confidentiality, and non-maleficence. Throughout the research process, the rights and wishes of the participants were fully respected and protected. The research team, after detailing the research objectives, implementation procedures, and potential benefits and risks, ensured that participants made voluntary decisions to participate with full knowledge. Additionally, participants had the right to withdraw from the study at any time without providing any reason. This study provided free examination services to each respondent, and all collected data were stored in a password-protected secure private computer accessible only to the research team members.

Muscle mass measurement and diagnosis of sarcopenia

Body weight was measured using a floor-mounted electronic scale, height was measured using a soft tape measure, muscle mass was estimated from appendicular skeletal muscle (ASM). According to the diagnostic criteria of sarcopenia updated by the Asian Working Group on Sarcopenia in 2019 (sarcopenia can be diagnosed when muscle mass is accompanied by muscle strength loss, or decreased physical activity, and severe sarcopenia is defined as comorbid muscle mass loss and decreased physical activity). Muscle mass was measured by bioelectrical impedance analysis (BIA) and height-adjusted skeletal muscle relative Index (RSMI) (M: <7.0kg/m2, F: <5.4 kg/m²) sarcopenia was diagnosed; Muscle strength is measured by grip strength (M: <28 kg, F: <18 kg) was diagnosed with decreased muscle strength; Physical activity measurement: 6 m walk <1.0m/S, or 5 chair sitting times >12s, or short physical performance battery (SPPB) <9 points can be assessed as a mobility disability [17]. Bioelectrical impedance analysis (BIA) is a widely used tool for assessing body composition as a portable, non-invasive, and low-cost method. Using BIA does not involve large amounts of ionizing radiation, costs are limited, can be done by almost anyone, and there is minimal difference between observers. The Asian Sarcopenia Working Group 2019 (AWGS 2019) introduced the concept of “probable sarcopenia”, defined as the presence of only low muscle strength or low physical performance, specifically for primary health care or community health promotion to enable earlier lifestyle interventions. Therefore, this study adopts the diagnostic criteria of BIA and AWGS 2019, which can easily and quickly diagnose the occurrence of sarcopenia in centenarians at an early stage.

Assessment of covariates

The following covariates were collected by trained follow-up: age, sex, education (any education or illiteracy), alcohol consumption status, and smoking status. Information on geriatric illnesses, including hearing problems, vision problems, disability, falls (past year), and fractures (any type), was collected by professionals using face-to-face interviews. The following chronic diseases that may be associated with mortality were also assessed: hypertension, diabetes, cardiovascular disease, respiratory disease, osteoarthritis disease, gastrointestinal disease, chronic kidney disease, prostate disease, and cancer. Disability was assessed using the self-reported activities of daily living (ADL) scale and Katz index, which was made according to the law of human function development. The six assessment items were arranged in the order of bathing, dressing, toileting, transferring, bowel and urine control, and eating. As defined by the Katz index, “no disability” was defined as independent completion of all items, “moderate disability” as dependence on one or two items, and “severe disability” as dependence on three or more items [18]. In addition, we measured upper arm muscle circumference (MAC) accurately to 0.1cm using millimeter-scale tape. Fasting venous blood samples were collected to determine blood glucose, blood lipid, serum albumin, hemoglobin and other biochemical indicators.

Survival status

From 2019, all subjects were followed up regularly by telephone by special follow-up personnel. If a participant died, the time from the beginning of the baseline data investigation to death was recorded, until the death of the last subject and the termination of the study, and the relevant data were recorded.

Statistical analysis

SPSS 25.0 for Windows (IBM Corporation, Armonk, NY) and R language software were used for statistical analysis. Continuous variables were expressed as mean ± standard deviation (SD) if they were normally distributed. Otherwise, they were expressed as median ± quartile. Categorical variables were expressed as absolute numbers and percentage of the total (%). Independent sample t test was used to compare the difference between the sarcopenia group and the normal muscle mass group for normal distribution of continuous variables, and Mann-Whitney U test was used for abnormal distribution of continuous variables. Pearson's chi-square test or Fisher’s exact test (with the expected cell count of < 5) was used for categorical variables. The proportional-hazards assumption was tested with the use of Schoenfeld residual test (P > 0.05). COX regression models were used to estimate hazard ratios (HRS) to identify independent predictors of mortality, adjusting for potential confounders (sleep disturbance, age, basal metabolic rate, and disability). P <0.05 was considered statistically significant. Kaplan-Meier curves were plotted by log-rank test to demonstrate the association between survival status and sarcopenia

Result

A total of 98 patients were included in our study, with an average age of 102.2 ± 1.8 years, 25 (25.5%) males, 73 (74.5%) females, 59 (60.2%) illiterate patients, 27 (27.6%) living in urban areas and 71 (72.4%) living in rural areas. There were 4 smokers (4.1%) and 17 drinkers (17.3%), respectively. The mean value of skeletal muscle mass (ASM) was 14.0 ± 3.5, the mean value of height-adjusted skeletal muscle relative index (RSMI) was 6.9 ± 1.1 kg/m2, the mean value of body mass index (BMI) was 20.8 ± 3.9, and the mean value of body fat percentage was 31.8 ± 10.2. The average visceral fat area was 72.4 ± 37.6, the average basal metabolic rate was 979.6 ± 128.5, and the MAC was 18.2 ± 2.3. There were 21 cases of hypertension (21.4%), 2 cases of diabetes (2.0%), 6 cases of respiratory diseases (6.1%), and 3 cases of cardiovascular diseases (3.1%). The results showed that the prevalence of chronic diseases in this population was not high. The score of ADL was 74.9 ± 29.2. According to Katz index, 47 (48.0%) had moderate disability, 10 (10.2%) had severe disability, 30 (30.6%) had osteoarthropathy, and 40 (40.9%) had sleep disorders. In the muscle strength test, 11 people could not complete the grip strength test, and the average grip strength of the rest was 8.53 ± 5.49, which was lower than the normal standard. In the physical activity test, the 6-meter walking time was > 6 s, and 7 people could complete 5 times of chair sitting, and the time was >12 s. The score of SPPB was <9, and the physical activity ability was poor. 20 patients (20.4%) had sarcopenia, and the average survival time was 27.3 ± 11.9 months. The specific data characteristics are shown in Table 1.

Table 1.

Characteristics of the sample

n (%) or mean (sd)
Socio-demographic characteristics
 Age 102.2±1.8
Sex(n,%
 Male 25(25.5)
 Female 73(74.5)
 Illiteracy 59(60.2)
 Residence - Rural area 71(72.4)
 ASM 14.0±3.5
 RSMI 6.9±1.1
 Body fat percentage 31.8±10.2
 BMI 20.8±3.9
 Bone mineral content 1.9±0.4
 MAC 18.2±2.3
 Visceral fat area 72.4±37.6
 Basal metabolic rate 979.6±128.5
 Current alcohol drinker (n, %)
 Current 10(10.2)
 Former 17(17.3)
 No 71(72.5)
Current smoker (n, %)
 Current 4(4.1)
 Former 11(11.2)
 No 83(84.7)
 HGB 112.9±17.1
 ALB (g/l) 36.3±4.1
 GLO (g/l) 30.0±4.5
 Fllow-up time (months) 27.3±11.9
Physical health
 Hearing problems 38(38.8)
 Vision problems (n, %) 19(19.4)
 osteoarthropathy 30(30.6)
 Hypertension 21(21.4)
 Diabetes 2(2.0)
 Cardiovascular disease 3(3.1)
 Respiratory diseases 6(6.1)
 stupid 1(1.0)
 Sleep disorder 45(45.9)
Functional status
 sarcopenia 20(20.4)
 Grip Strength 8.5±5.5
 SPPB 2.8±2.2
 Disability 57(58.2)
 ADL 74.9±29.2

ASM Appendicular skeletal muscle mass, RSMI Relative skeletal muscle index, BMI Body Mass Index, MAC Mid arm circumference, HGB Hemoglobin, ALB Albumin, GLO Globulin, SPPB Short Physical Performance Battery, ADL Activities of daily living

We followed up for 54 months until the end of the study when the last elderly died, and all the sarcopenia subjects died at 34 months of follow-up. The baseline characteristics of the centenarians in the two groups are shown in Table 2; 20 centenarians (20.4%) were in the sarcopenia group and 78 centenarians (79.6%) were in the normal muscle mass group. The study found that compared with the normal muscle mass group, the sarcopenia group was older (103.15 ± 2.18 VS 102 ± 1.68, P < 0.05) and had a shorter survival time (15.8 ± 6.6 VS 30.3 ± 11.1, P < 0.001). The mortality rate of one, two and three years was higher than that of normal muscle mass group, the difference was statistically significant. In addition, BMI, ASM, RSMI, MAC, Bone mineral content (BMC) and Basal metabolic rate (BMR) in the sarcopenia group were lower than those in the normal muscle mass group. However, Body fat percentage and Visceral fat area were higher than those in the normal muscle mass group, and there were statistical differences between the two groups. Kaplan-Meier method was used to compare the effects of sarcopenia and normal muscle groups on the survival time of centenarians, and the survival curves of subjects with sarcopenia and normal muscle mass are shown in Fig. 1. log-rank test showed the mean survival time of normal muscle mass was (30.3 ± 11.1) months and that of sarcopenia group was (15.8 ± 6.6) months, Chi-square value was 36.2, the survival time of the two groups was statistically different (P < 0.001), as shown in Fig. 1.

Table 2.

Baseline characteristics of the study population

Variable Total n=98 Nomal mass n=78 Sarcopenia mass n=20 P value
Age(years) 102.2±1.8 102.0±1.7 103.2±2.2 0.038
Sex(n, %) 0.774
 Male 25(25.5) 19(24.4) 6(30.0)
 Female 73(74.5) 59(75.6) 14(70.0)
Illiteracy (n, %) 59(60.2) 46(59.0) 13(65.0) 0.799
Current smoker (n, %) 0.373
 Current 4(4.1) 4(5.1) 0(0)
 Former 11(11.2) 7(9.0) 4(20.0)
 No 83(84.7) 67(85.9) 16(80.0)
Current alcohol drinker (n, %) 0.843
 Current 10(10.2) 13(16.7) 4(20.0)
 Former 17(17.3) 9(11.5) 1(5.0)
 No 71(72.5) 56(71.8) 15(75.0)
Geriatric conditions
 ASM (kg) 14.0±3.5 14.8±3.2 11.0±3.3 <0.001
 BMI (kg/m2) 20.8±3.9 21.2±3.8 19.0±3.5 0.021
 RSMI (kg/m2) 6.9±1.1 7.2±1.0 5.6±0.8 <0.001
 MAC (cm) 18.2±2.3 18.4±2.5 17.3±1.5 0.064
 Body fat percentage (%) 31.8±10.2 30.8±9.9 35.9±10.5 0.045
 Bone mineral content (kg) 1.9±0.4 2.0±0.5 1.7±0.3 0.020
 Visceral fat area (m2) 72.4±37.6 68.7±37.2 87.2±36.4 0.049
 Basal metabolic rate (kcal) 979.6±128.5 1006.9±115.6 873.2±123.2 <0.001
 Mortality Rate (n, %) 73(74.5) 53(67.9) 20(100.0) 0.003
 Survival time (month) 27.5±11.5 30.3±11.1 15.8±6.6 <0.001
 HGB (g/L) 112.9±17.1 113.6±16.9 110.1±17.8 0.411
 ALB (g/L) 36.3±4.1 36.4±4.0 35.9±4.4 0.678
 Grip Strength (kg) 8.5±5.5 7.8±5.6 7.2±6.5 0.711
 ADL impairment (n, %) 22(22.4) 17(21.8) 5(25.0) 0.768
 Vision problems (n, %) 19(19.4) 13(16.7) 6(30.0) 0.209
 Hearing problems (n, %) 38(38.8) 29(37.2) 9(45.0) 0.609
 Sleep disorder (n, %) 45(45.9) 47(60.3) 11(55.0) 0.800
 Disability (n, %) 57(58.2) 44(56.4) 13(65.0) 0.614
Chronic diseases
 Hypertension (n, %) 21(21.4) 19(24.4) 2(10.0) 0.227
 Respiratory diseases (n, %) 6(6.1) 5(6.4) 1(5.0) 1
 Diabetes (n, %) 2(2.0) 2(2.6) 0(0.0) 1

The comparison of Chinese centenarians with sarcopenia and nomal mass group was shown as mean and standard deviation for continuous variables and percentage for categorical variables. Pearson Chi-square test or Fisher exact test were used for categorical variables, independent sample t test was used for continuous variables, P<0.05 was considered to be statistically significant

ASM Appendicular skeletal muscle mass, RSMI Relative skeletal muscle index, BMI Body Mass Index, MAC Mid arm circumference, HGB Hemoglobin, ALB Albumin, ADL Activities of daily living

Fig. 1.

Fig. 1

COX regression analysis was performed according to muscle mass index and survival time, and the survival curve was tested by log-rank. P < 0.001, The blue curve is normal muscle mass group, and the red curve is sarcopenia group

We used the COX regression model to calculate the hazard ratio (HR) of death. Univariate analysis showed that the risk of death in the sarcopenia group was 4.82 times higher than that in the normal muscle group. The regression model was adjusted for confounding factors, and the model was adjusted for sleep disorders, age, basal metabolic rate, and disability. The hazard ratio (HR) and 95% confidence interval (CI) for death of each related variable in the model were shown in Table 3. Sarcopenia was also a risk factor for death in centenarians, with a 3.64-fold increase in the risk of death (HR = 4.64, 95%CI: 2.48–8.66, P < 0.001). At the same time, it was found that age (HR = 1.16, 95%CI: 1.04–1.28, P = 0.006) and disability (HR = 1.56, 95%CI: 1.01–2.40, P = 0.045) were also risk factors for death. The forest plot of death hazard ratio of each variable was drawn by R language software, as shown in Fig. 2.

Table 3.

Multiple regression analysis of centenarian mortality

Variable HR HR 95% CI P value
RSMI 4.64 2.48-8.66 <0.001
Sleep disorder 1.44 0.91-2.28 0.116
Age 1.16 1.04-1.28 0.006
Basal metabolic rate 1.00 0.99-1.00 0.051
Disability 1.56 1.01-2.40 0.045

Fig. 2.

Fig. 2

Multiple COX regression analysis model forest map, it shows that sarcopenia, age and disability are risk factors for increased mortality in centenarians

COX regression models adjusted for confounders, the association between sarcopenia and long-term death in centenarians was expressed as a hazard ratio (95% CI), and the models adjusted for sleep disorders, age, basal metabolic rate, and disability, sarcopenia remains a risk factor for death in centenarians.

In addition, we carried out COX univariate regression analysis of sarcopenia and one-year, two-year, and three-year mortality as shown in Table 4. The results showed that sarcopenia was associated with the annual mortality of centenarians, and the difference was statistically significant (P < 0.05). Comparing the survival curves of one year, two years and three years, there were statistical differences, as shown in Fig. 3.

Table 4.

COX regression univariate analysis of sarcopenia and annual mortality

variable b-coefficient wald HR 95%CI P value
One-year mortality rate 2.237 9.982 9.367 2.338-37.526 0.002
two-year mortality rate 1.847 31.086 6.339 3.312-12.133 <0.001
three-year mortality rate 1.761 37.826 5.819 3.320-10.200 <0.001

Fig. 3.

Fig. 3

The survival curves of the relationship between sarcopenia and death for one year, two years and three years, respectively, can be seen to be associated with sarcopenia

Discussion

As far as I know, our study is the first to examine sarcopenia as a predictor of long-term mortality risk in centenarians. The average age of the subjects in our study was 102.2 ± 1.8 years. The average height adjusted relative skeletal muscle index (RSMI) was 7.2 ± 1.0 (kg/m2) in the normal muscle mass group and 5.6 ± 0.8 (kg/m2) in the sarcopenia group, and the incidence of sarcopenia was 20.4%. Compared with the normal muscle mass group, the survival time of the sarcopenia group was shorter (15.8 ± 6.6 VS 30.3 ± 11.1, P < 0.001), and the one, two, and three-year mortality rates were higher than those of the normal muscle mass group, and the difference was statistically significant. There was no statistical difference between the sarcopenia group and the normal muscle mass group in gender, education level, prevalence of chronic diseases, smoking, drinking and other basic information. COX regression, univariate analysis showed that sarcopenia was a risk factor for death in centenarians. Regression models removed confounding factors such as sleep disorders, age, basal metabolic rate, and disability, and sarcopenia remained a risk factor for centenarian death. The risk of death increased by 3.64 times (HR = 4.64, 95%CI: 2.48–8.66, P < 0.001). Simultaneous discovery, Age and disability were also risk factors for death in centenarians.

As a model of healthy aging, centenarians are considered to have successfully experienced aging and moved toward longevity [19]. Centenarians generally have fewer chronic diseases than non-centenarians, and their health tends to change more slowly until age 85 [20]. The low incidence of chronic diseases such as hypertension, diabetes, and respiratory and cardiovascular diseases among centenarians in our study is consistent with previous studies. However, as we age, the body is in the process of continuous aging, and aging can lead to age-related muscle degeneration, resulting in the overall loss of skeletal muscle throughout the body. Cellular changes in sarcopenia include a reduction in muscle fiber size and number, especially type II fibers, ultimately leading to reduced muscle mass and decreased strength [21]. Therefore, sarcopenia is inevitable in the aging process and mainly manifests as a progressive loss of skeletal muscle mass accompanied by a loss of muscle strength [22]. which was 20.4% in our study, and is relatively high compared with previous reports of sarcopenia in people over 60 years of age in the world, which ranged from 10 to 27% [23]. Therefore, the occurrence of sarcopenia in centenarians should attract our attention, then how does sarcopenia affect the health of centenarians?

Sarcopenia is a progressive and systemic skeletal muscle disease involving accelerated loss of muscle mass and function. Characterized by the excessive loss of muscle mass, strength and function with advancing age. Consequences of sarcopenia include increased risk of frailty and earlier mortality, significant loss of quality of life and considerable healthcare expenditure [24–27]. It typically occurs in older adults and is an age-related process influenced not only by contemporaneous risk factors but also by factors such as genetics and lifestyle throughout the life course [28]. Previous studies have shown that sarcopenia is a significant risk factor for mortality in elderly patients. A meta-analysis of 17 articles included 11 studies on the effect of sarcopenia on mortality in elderly patients, and the statistical results showed that the mortality rate was significantly higher in patients with sarcopenia, especially in subjects aged 79 years and older [29]. In another systematic review and meta-analysis, sarcopenia was confirmed to be a predictor of all-cause mortality in community older adults [30]. Sarcopenia has also been reported to be a prevalent syndrome associated with premature mortality among older adults in the community [31]. Landi et al. conducted a 7-year prospective study and found that sarcopenia was associated with high mortality in frail community older adults aged ≥ 80 years, with sarcopenia increasing mortality by 2.32-fold [32]. Our study also found that sarcopenia was a risk factor for long-term mortality in centenarians, and the risk of death was 3.64 times higher than that in the normal muscle mass group, consistent with the above research. Moreover, the 1-year, 2-year, and 3-year mortality rates were significantly increased. At the same time, the body fat percentage and visceral fat area in the sarcopenia group were higher than those in the normal group, and the differences were statistically significant. Studies have found that the increase in body fat percentage and visceral fat content leads to arterial inflammation, increases the prevalence of cardiovascular disease, and even prone to depression, and may disrupt metabolism and induce cancer [33], At the same time, sarcopenia can affect the movement and autonomous activities of the elderly, increasing disability, falls and fall-related injuries, affecting the physical health of the elderly [7, 8], which may be the cause of increased mortality and earlier death time in the sarcopenia group. This study also found that the sarcopenia group had lower muscle strength (grip strength value) and independent living performance (ADL score) than the normal muscle mass group, although the difference was not statistically significant. But these findings could suggest that sarcopenia centenarians may be more frail and less resistant to disease and external stimuli, thereby increasing mortality.

However, some studies have found that sarcopenia can be reversed by intervention and treatment, and EWGSOP2 emphasizes that it is increasingly possible to prevent, delay, treat and even reverse sarcopenia through early and effective intervention [3]. A study on the treatment of sarcopenia showed that basic physical activity with resistance combined with protein or protein-rich diet can improve the sarcopenia state [34]. For the treatment of exercise intervention in elderly patients with sarcopenia, two systematic reviews have shown that exercise intervention can significantly improve muscle strength, quality and balance in patients with sarcopenia [35, 36]. In a Chinese study of 4000 subjects over 65 years of age, the initial incidence of sarcopenia was 9.0%, and 18.8% of subjects had sarcopenia reversal after diet and exercise intervention during 4 years of follow-up [37]. Therefore, although sarcopenia is an inevitable age-related disease in the aging process, if it can be screened and diagnosed at an early stage, some intervention measures can be taken to delay or even reverse the occurrence of sarcopenia, and the life expectancy of the elderly may be improved.

In conclusion, sarcopenia is a risk factor for death in the elderly and centenarians, but it is a reversible disease of aging. If early intervention and treatment of centenarians with sarcopenia are carried out, the occurrence of sarcopenia can be reversed, a series of hazards can be reduced, and the survival time of the elderly can be prolonged, human beings may continue to break through the limit of life. Therefore, early screening and definitive diagnosis of sarcopenia are essential. At present, there is no unified diagnostic criteria for sarcopenia in the world. Among them, The most used definition is the revised European Working Group on Sarcopenia in the Elderly (EWGSOP) 2019 (EWGSOP2) diagnostic criteria [38], the 2019 Asian Working Group on Sarcopenia (AWGS) [17], the International Working Group on Sarcopenia (IWGS) [39], and the Foundation of National Institutes of Health (FNIH) [5]. Due to the differences in body size and lifestyle between Chinese and Western peers, the 2019 Asian Working Group criteria for sarcopenia were selected for diagnosis in our study. In addition, we used bioelectrical impedance analysis (BIA) to measure muscle mass, and height adjusted relative skeletal muscle index (RSMI) was used to reduce inter-individual differences and make the measurement results more accurate. BIA is a portable, noninvasive, and inexpensive tool for body composition assessment. The use of BIA does not involve large amounts of ionizing radiation, is low cost, can be performed on almost everyone, and there is little interobserver variation. BIA has been validated in healthy populations and patients with chronic diseases, and validated BIA equations have been established based on age, sex, and race [40, 41]. It provides convenience for the rapid screening and diagnosis of sarcopenia in elderly patients.

The limitations of this study are that due to the particularity of the centenarian population, the number of samples is relatively small, and because of the impact of novel coronavirus Disease 2019 (COVID-19), there is no way to obtain the specific cause of death of the subjects, this may compromise the generalizability of the study and obscure the true causes of death among the subjects; The limited geographical scope of patients included in this study, and the absence of examination of inflammatory markers and nutritional status of participants, may have biased the results; In addition, this study was only observational and did not intervene in the subjects with sarcopenia. In the follow-up study, we will expand the collection of the areas where the subjects live, increase the sample size, and carry out randomized controlled studies to conduct treatment and intervention for patients with sarcopenia, and compare the mortality of the two groups of patients, so as to further verify the correlation between sarcopenia and centenarians. Enhance the credibility of the research.

Conclusion

Sarcopenia can serves as an important and independent predictor of long-term death in centenarians. If sarcopenia can be discovered early, timely exercise, diet intervention and treatment can reverse the occurrence of sarcopenia and reduce a series of hazards brought by it, which can extend the survival time of the elderly, and human beings may continue to break the limit of life. This provides new ideas for us to explore the longevity of the elderly, and is our future research focus and direction of effort.

Acknowledgements

Not applicable.

Abbreviations

BIA

Bioelectrical Impedance Analysis

AWGS

Asian Working Group Sarcopenia

BMI

Body Mass Index

ALM

Appendicular Lean Mass

ASM

Appendicular Skeletal Muscle

RSMI

Relative Skeletal Muscle Index

SPPB

Short Physical Performance Battery

IWGS

International Working Group On Sarcopenia

FNIH

Foundation Of National Institutes Of Health

Authors’ contributions

Y. T and HY. L wrote the main manuscript and completed the statistical analysis and collation of the data; L.W managed the research and wrote and revised the manuscript; MJ. C, YY. Z and XC. W edited and collated the chart of the article. All authors reviewed the manuscript.

Funding

This work was supported by 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (Grant No. ZY2017201).

Data availability

The datasets supporting the conclusion of this study are available from the corresponding author upon request.

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the People’s Hospital of Leshan [Le shi Hospital Committee [2019] No.15], the trial was registered at the Chinese Clinical Trial Center on 2018. Trial registration numbers 2018 − 463; ChiCTR1900020754. All subjects signed informed consent forms.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Yun Tang and Hongyan Lin contributed equally to this work and share first authorship.

References

  • 1.World Health Organization. Ageing and health. World Health Organization. Retrieved October 20, 2024, from https://www.who.int/zh/news-room/fact-sheets/detail/ageing-and-health [EB/OL]. 2024.
  • 2.Robine JM, Cubaynes S. Worldwide demography of centenarians. Mech Ageing Dev. 2017;165Pt B:59–67. 10.1016/j.mad.2017.03.004. [DOI] [PubMed] [Google Scholar]
  • 3.Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. 10.1093/ageing/afy169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Chen Lk L, Wj P, Ln, et al. Recent advances in sarcopenia research in asia: 2016 update from the Asian working group for sarcopenia. J Am Med Dir Assoc. 2016;17(8):e7671–7677677. 10.1016/j.jamda.2016.05.016. [DOI] [PubMed] [Google Scholar]
  • 5.Studenski SA, Peters KW, De et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol Series A Biol Sci Med Sci. 2014;69(5):547–558. 10.1093/gerona/glu010. [DOI] [PMC free article] [PubMed]
  • 6.Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127(5 Suppl):S990–1. 10.1093/jn/127.5.990S. [DOI] [PubMed] [Google Scholar]
  • 7.Srikanthan P, Al H, Karlamangla As. Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the National health and nutrition examination survey III. PLoS ONE. 2010;5(5):e10805. 10.1371/journal.pone.0010805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Chin So R, Sy, Chon S, et al. Sarcopenia is independently associated with cardiovascular disease in older Korean adults: the Korea National health and nutrition examination survey (KNHANES) from 2009. PLoS ONE. 2013;8(3):e60119. 10.1371/journal.pone.0060119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Cheung Cl L, Ks, Cheung Bm. Evaluation of cutpoints for low lean mass and slow gait speed in predicting death in the National health and nutrition examination survey 1999–2004. Ser Biol Sci Med Sci. 2016;71(1):90–5. 10.1093/gerona/glv112. The journals of gerontology. [DOI] [PubMed] [Google Scholar]
  • 10.Gümüşsoy m, Atmış V, Yalçın A, et al. Malnutrition-sarcopenia syndrome and all-cause mortality in hospitalized older people. Clin Nutr. 2021;40(11):5475–81. 10.1016/j.clnu.2021.09.036. [DOI] [PubMed] [Google Scholar]
  • 11.Kwon Ye L, Js K, Jy, et al. Impact of sarcopenia and phase angle on mortality of the very elderly. J cachexia Sarcopenia Muscle. 2023;14(1):279–87. 10.1002/jcsm.13128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Teixeira L, Araújo L, Paúl C, et al. Further survival at age 100: findings from the Oporto centenarian study. Exp Gerontol. 2020;133:110854. 10.1016/j.exger.2020.110854. [DOI] [PubMed] [Google Scholar]
  • 13.Mossakowska M, Broczek K, Wieczorowska-Tobis K et al. Cognitive performance and functional status are the major factors predicting survival of centenarians in poland. The journals of gerontology. Series A, biological sciences and medical sciences. 2014;69(10):1269–75. 10.1093/gerona/glu003. [DOI] [PubMed]
  • 14.Tiainen K, Luukkaala T, Hervonen A, et al. Predictors of mortality in men and women aged 90 and older: a nine-year follow-up study in the vitality 90 + study. Age Ageing. 2013;42(4):468–75. 10.1093/ageing/aft030. [DOI] [PubMed] [Google Scholar]
  • 15.Zou C, Zhou Y, Dong B, et al. Predictors of 49-month mortality in Chinese nonagenarians and centenarians in PLAD study. Aging Clin Exp Res. 2015;27(6):821–7. 10.1007/s40520-015-0355-y. [DOI] [PubMed] [Google Scholar]
  • 16.Wang H, Hai S, Liu Y, et al. Skeletal muscle mass as a mortality predictor among nonagenarians and centenarians: A prospective cohort study. Sci Rep. 2019;9(1):2420. 10.1038/s41598-019-38893-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Chen Lk, Woo J, Assantachai P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300–e3072. 10.1016/j.jamda.2019.12.012. [DOI] [PubMed] [Google Scholar]
  • 18.Katz S, Ford Ab M, Rw, et al. Studies of illness in The aged. The index of adl: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914–9. 10.1001/jama.1963.03060120024016. [DOI] [PubMed] [Google Scholar]
  • 19.Franceschi C, Passarino G, Mari D, et al. Centenarians as a 21st century healthy aging model: A legacy of humanity and the need for a world-wide consortium (WWC100+). Mechanisms of ageing and development. 2017;165(Pt B);55–8. 10.1016/j.mad.2017.06.002. [DOI] [PubMed]
  • 20.Vetrano Dl, Grande G, Marengoni A et al. Health trajectories in Swedish centenarians. The journals of gerontology. Series A, biological sciences and medical sciences. 2021;76(1):157–63. 10.1093/gerona/glaa152. [DOI] [PMC free article] [PubMed]
  • 21.Correa-De-Araujo R, Harris-Love Mo, Miljkovic I et al. The Need for Standardized Assessment of Muscle Quality in Skeletal Muscle Function Deficit and Other Aging-Related Muscle Dysfunctions: A Symposium Report. Frontiers in physiology. 2017;8:87. 10.3389/fphys.2017.00087. [DOI] [PMC free article] [PubMed]
  • 22.Traub J, Bergheim I, Eibisberger M, et al. Sarcopenia and liver Cirrhosis-Comparison of the European working group on sarcopenia criteria 2010 and 2019. Nutrients. 2020;12(2):547. 10.3390/nu12020547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Petermann-Rocha F, Balntzi V, Gray Sr, et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J cachexia Sarcopenia Muscle. 2022;13(1):86–99. 10.1002/jcsm.12783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Shaw SC, Dennison EM, Cooper C. Epidemiology of sarcopenia: determinants throughout the lifecourse. Calcif Tissue Int. 2017;101:229–47. 10.1007/s00223-017-0277-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Westbury LD, Harvey NC, Beaudart C, et al. Predictive value of sarcopenia components for all-cause mortality: findings from population-based cohorts. Aging Clin Exp Res. 2024;36(1):126. 10.1007/s40520-024-02783-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Beaudart C, Tilquin N, Abramowicz P, et al. Quality of life in sarcopenia measured with the SarQoL questionnaire: A meta analysis of individual patient data. Maturitas. 2024;180:107902. 10.1016/j.maturitas.2023.107902. [DOI] [PubMed] [Google Scholar]
  • 27.Pinedo-Villanueva R, Westbury LD, Syddall HE, et al. Health care costs associated with muscle weakness: A UK Population-Based estimate. Calcif Tissue Int. 2019;104:137–44. 10.1007/s00223-018-0478-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Cruz-Jentoft Aj, Sayer Aa. Sarcopenia. Lance (London. England). 2019;393(10191):2636–46. 10.1016/S0140-6736(19)31138-9. [DOI] [PubMed]
  • 29.Beaudart C, Zaaria M, Pasleau F, et al. Health outcomes of sarcopenia: A systematic review and Meta-Analysis. PLoS ONE. 2017;12(1):e0169548. 10.1371/journal.pone.0169548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Liu P, Hao Q, Hai S, et al. Sarcopenia as a predictor of all-cause mortality among community-dwelling older people: A systematic review and meta-analysis. Maturitas. 2017;103:16–22. 10.1016/j.maturitas.2017.04.007. [DOI] [PubMed] [Google Scholar]
  • 31.Jc B, Mo H, Harhay Mn. Sarcopenia and mortality among a population-based sample of community-dwelling older adults. J cachexia Sarcopenia Muscle. 2016;7(3):290–8. 10.1002/jcsm.12073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Landi F, Cruz-Jentoft Aj, Liperoti R, et al. Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from IlSIRENTE study. Age Ageing. 2013;42(2):203–9. 10.1093/ageing/afs194. [DOI] [PubMed] [Google Scholar]
  • 33.Castro-Barquero S, Casas R, Rimm EB, et al. Loss of visceral fat is associated with a reduction in inflammatory status in patients with metabolic syndrome. Mol Nutr Food Res. 2023;67(4):e2200264. 10.1002/mnfr.202200264. [DOI] [PubMed] [Google Scholar]
  • 34.Dent E, Morley Je C-J, Aj, et al. International clinical practice guidelines for sarcopenia (ICFSR): screening, diagnosis and management. J Nutr Health Aging. 2018;22(10):1148–61. 10.1007/s12603-018-1139-9. [DOI] [PubMed] [Google Scholar]
  • 35.Lozano-Montoya I, Correa-Pérez A, Abraha I, et al. Nonpharmacological interventions to treat physical frailty and sarcopenia in older patients: a systematic overview - the SENATOR project ONTOP series. Clin Interv Aging. 2017;12:721–40. 10.2147/CIA.S132496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Vlietstra L, Hendrickx W, Waters Dl. Exercise interventions in healthy older adults with sarcopenia: A systematic review and meta-analysis. Australas J Ageing. 2018;37(3):169–83. 10.1111/ajag.12521. [DOI] [PubMed] [Google Scholar]
  • 37.Yu R, Wong M, Leung J, et al. Incidence, reversibility, risk factors and the protective effect of high body mass index against sarcopenia in community-dwelling older Chinese adults. Geriatr Gerontol Int. 2014;14(Suppl 1):15–28. 10.1111/ggi.12220. [DOI] [PubMed] [Google Scholar]
  • 38.Chen Lk, Woo J, Assantachai P, Auyeung Tw, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300–e3072. 10.1016/j.jamda.2019.12.012. [DOI] [PubMed] [Google Scholar]
  • 39.Fielding Ra, Vellas B, Evans Wj, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12(4):249–56. 10.1016/j.jamda.2011.01.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Kyle Ug, Bosaeus I, De Lorenzo Ad, et al. Bioelectrical impedance analysis–part I: review of principles and methods. Clinical Nutr (Edinburgh Scotland). 2004;23(5):1226–43. 10.1016/j.clnu.2004.06.004. [DOI] [PubMed]
  • 41.Kyle Ug, Bosaeus I, De Ad L, et al. Bioelectrical impedance analysis-part II: utilization in clinical practice. Clin Nutr. 2004;23(6):1430–53. 10.1016/j.clnu.2004.09.012. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets supporting the conclusion of this study are available from the corresponding author upon request.


Articles from BMC Geriatrics are provided here courtesy of BMC

RESOURCES